Effect of Exercise Training on Salivary Immunoglobulin A in Patients With Chronic Obstructive Pulmonary Disease
2 other identifiers
interventional
35
1 country
2
Brief Summary
The purpose of this study is to determine whether whole body exercise training alters the immunity in the lungs of people with COPD and reduces the incidence of chest infections over the longer term.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Apr 2014
Longer than P75 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 11, 2014
CompletedStudy Start
First participant enrolled
April 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2017
CompletedFirst Posted
Study publicly available on registry
October 27, 2020
CompletedOctober 27, 2020
October 1, 2020
3.2 years
March 11, 2014
October 21, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in Salivary Immunoglobulin A levels
SIgA
Change over 8 weeks
Secondary Outcomes (5)
Change in circulatory inflammatory markers
Change over 8 weeks
Change in physical activity levels
Change over 8 weeks
Health status
Change over 8 weeks
Exercise capacity (6MWT)
Change over 8 weeks
Number of acute exacerbations
12 months
Study Arms (2)
Pulmonary rehabilitation
EXPERIMENTAL8 weeks of pulmonary rehabilitation (twice weekly training) Exercise and education sessions accompanied by home exercise program
Control group
NO INTERVENTIONUsual medical treatment for 8 week period
Interventions
8 weeks of exercise training (twice weekly) of education and exercise
Eligibility Criteria
You may qualify if:
- Diagnosis of COPD (FEV1/FVC \< 70), smoking Hx of minimum of 10 pack years
You may not qualify if:
- Diagnosis of asthma, bronchiectasis, attendance at pulmonary rehabilitation within last 12 months, exacerbation of COPD within last 4 weeks
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Bayside Healthlead
- Austin Healthcollaborator
- Newcastle Universitycollaborator
Study Sites (2)
Alfred Health
Melbourne, Victoria, 3004, Australia
Austin Health
Melbourne, Victoria, 3084, Australia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Anne Holland, PhD
Alfred Health, La Trobe University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 11, 2014
First Posted
October 27, 2020
Study Start
April 1, 2014
Primary Completion
June 30, 2017
Study Completion
June 30, 2017
Last Updated
October 27, 2020
Record last verified: 2020-10